Researchers in the Department of Pharmaceutical Analysis at the National Institute of Pharmaceutical Education and Research (Punjab, India) have published new research using liquid chromatography-mass spectrometry (LC-MS) tools to characterize degradation products of the nonsteroidal anti-inflammatory drugs piroxicam and meloxicam.
Researchers in the Department of Pharmaceutical Analysis at the National Institute of Pharmaceutical Education and Research (Punjab, India) have published new research using liquid chromatography–mass spectrometry (LC–MS) tools to characterize degradation products of the nonsteroidal anti-inflammatory drugs piroxicam and meloxicam.
The degradation behavior of the two drugs was studied by subjecting the drugs individually to hydrolytic (acidic, basic, and neutral), oxidative, photolytic, and thermal stress. Both drugs showed significant degradation in hydrolytic, oxidative, and photoneutral conditions, although they were stable under dry heat and on exposure to light in the solid state. In total, five and four degradation products were formed from piroxicam and meloxicam, respectively. To characterize the degradation products, mass fragmentation pathways of both drugs were established using mass spectrometry–time of flight (MS-TOF), multiple-stage mass spectrometry (MSn), and hydrogen–deuterium (H/D) exchange mass studies, followed by LC–MS-TOF and on-line H/D exchange experiments on the degradation products.
The collected data helped to identify the degradation products of both the drugs. The researchers were able to establish degradation pathways and proposed mechanisms for the formation of the degradation products.
The study was published on-line on 18 October as an advance article in the journal Analytical Methods.
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.